Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04162210
Title Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline

multiple myeloma


Dexamethasone + Pomalidomide

belantamab mafodotin-blmf

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.